Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ImmunityBio (IBRX) Cash from Financing Activities (2016 - 2025)

ImmunityBio (IBRX) has disclosed Cash from Financing Activities for 12 consecutive years, with $54.9 million as the latest value for Q4 2025.

  • On a quarterly basis, Cash from Financing Activities fell 48.66% to $54.9 million in Q4 2025 year-over-year; TTM through Dec 2025 was $400.2 million, a 42.12% increase, with the full-year FY2025 number at $400.2 million, up 42.12% from a year prior.
  • Cash from Financing Activities was $54.9 million for Q4 2025 at ImmunityBio, down from $173.5 million in the prior quarter.
  • In the past five years, Cash from Financing Activities ranged from a high of $326.0 million in Q4 2021 to a low of -$982000.0 in Q1 2025.
  • A 5-year average of $99.0 million and a median of $87.6 million in 2021 define the central range for Cash from Financing Activities.
  • Peak YoY movement for Cash from Financing Activities: surged 289513.33% in 2023, then crashed 109.6% in 2025.
  • ImmunityBio's Cash from Financing Activities stood at $326.0 million in 2021, then plummeted by 66.27% to $109.9 million in 2022, then surged by 82.41% to $200.5 million in 2023, then plummeted by 46.68% to $106.9 million in 2024, then tumbled by 48.66% to $54.9 million in 2025.
  • Per Business Quant, the three most recent readings for IBRX's Cash from Financing Activities are $54.9 million (Q4 2025), $173.5 million (Q3 2025), and $172.8 million (Q2 2025).